Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Public ClinicalTrials.gov record NCT00027820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer. Stem cells are "seed cells" necessary to make blood cells. Researchers want to see if using less radiation and less chemotherapy with new immune suppressing drugs will enable a stem cell transplant to work. Researchers are hoping to see a mixture of recipient and donor stem cells after transplant. This mixture of donor and recipient stem cells is called "mixed-chimerism". Researchers hope to see these donor cells eliminate tumor cells. This is called a "graft-versus-leukemia" response.
Study identification
- NCT ID
- NCT00027820
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 106 participants
Conditions and interventions
Conditions
- Adult Acute Myeloid Leukemia in Remission
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Acute Myeloid Leukemia in Remission
- Childhood Myelodysplastic Syndrome
- Childhood Renal Cell Carcinoma
- Chronic Myelomonocytic Leukemia
- Clear Cell Renal Cell Carcinoma
- de Novo Myelodysplastic Syndrome
- Metastatic Renal Cell Cancer
- Previously Treated Myelodysplastic Syndrome
- Progression of Multiple Myeloma or Plasma Cell Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult Non-Hodgkin Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Non-Hodgkin Lymphoma
- Refractory Anemia
- Refractory Anemia With Ringed Sideroblasts
- Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Renal Medullary Carcinoma
- Type 1 Papillary Renal Cell Carcinoma
- Type 2 Papillary Renal Cell Carcinoma
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Adult Acute Myeloid Leukemia
- Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
- Fludarabine Phosphate Drug
- Total-Body Irradiation Radiation
- Peripheral Blood Stem Cell Transplantation Procedure
- Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Cyclosporine Drug
- Mycophenolate Mofetil Drug
Drug · Radiation · Procedure
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2001
- Primary completion
- Aug 31, 2004
- Completion
- Sep 4, 2004
- Last update posted
- Dec 19, 2019
2001 – 2004
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Health Sciences Center | Tucson | Arizona | 85724 | — |
| Stanford University Hospitals and Clinics | Stanford | California | 94305 | — |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Baylor Medical Center at Garland | Garland | Texas | 75042 | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00027820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2019 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00027820 live on ClinicalTrials.gov.